MINNEAPOLIS, July 29, 2024 — Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio’s $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. Bio-Techne joined Foresite Capital, and other investors, in this funding round.

Founded in 2021 and headquartered in Woburn, Massachusetts, Spear Bio is an innovative leader in the development, and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. Spear Bio’s proprietary Successive Proximity Extension Amplification Reaction (SPEAR) technology is exclusively licensed from the Wyss Institute for Biologically Inspired Engineering at Harvard University. SPEAR leverages target-binding probes that bind to proximal sites in a protein’s structure. This double-tagging event enables the two specially-designed probes to “shake hands” multiple times under a time-controlled manner to ensure true target-induced proximity and synthesize a unique DNA sequence which can then be amplified and quantified using standard qPCR instruments. In the absence of target protein, the transient interaction between free-floating probes does not allow multiple “shake hands” to initiate the synthesis of the amplifiable DNA sequence, reducing background over three orders of magnitude compared to conventional proximity-based assays. The ultra-sensitivity offered by Spear Bio’s technology makes it ideal for measuring historically challenging low abundant biomarkers in neurology, inflammation and oncology. The initial offering will focus on key biomarkers supporting translational research in Alzheimer’s disease.

“We are excited to invest in Spear Bio,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “Spear Bio’s ultra-sensitive detection technology offers significant advantages over traditional immunoassay and next-gen proteomic technologies, enabling the quantification of mere dozens of protein molecules in a sample. This level of sensitivity unlocks several challenging applications and high growth markets, including early diagnosis of neurodegenerative diseases. Importantly, Spear Bio’s assays run on qPCR equipment, which is routinely found in research and clinical facilities, representing an existing installed base to run these groundbreaking assays.”

“Having an industry leader like Bio-Techne invest in Spear Bio is a testament to the high potential of the SPEAR technology,” said Feng Xuan, Ph.D., Cofounder and Chief Executive Officer of Spear Bio. “Following this funding round, Spear Bio is ideally positioned to rapidly deploy our next-generation assay technology and enable the detection of biomarkers in historically challenging conditions, including neurodegenerative diseases.”

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

About Spear Bio
Spear Bio – founded in 2021 and headquartered in Woburn, Massachusetts – is an innovative leader in providing scalable solutions for ultra-sensitive protein biomarker measurements. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar level from sub-microliter sample volume. Spear Bio is focused on leveraging its technology’s unprecedented sensitivity to transform protein research and early disease diagnosis.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
[email protected] 
612-656-4416

SOURCE Bio-Techne Corporation

• Ledger Cathay Fund’s investment on BitcoinFi with Mezo commits to supercharging the evolution of the global Bitcoin Finance ecosystem
• Strategic investment plus prior funding led by Pantera Capital brings Mezo’s total amount raised to $30M

NEW YORK, July 26, 2024 — Thesis, one of the longest-standing venture studios funding and building brands on Bitcoin, today announced its strategic funding round led by Ledger Cathay Fund, Ledger and Cathay Innovation’s early-stage venture fund, for Mezo, its permissionless Bitcoin Economic Layer. This brings total funding for Mezo to $30M following its launch in April 2024. Other investors in the strategic round include ArkStream, Aquarius Fund, Flowdesk, GSR, Origin Protocol and Bybit ecosystem project, Mantle’s EcoFund.

Mezo will use this investment to accelerate technology development and grow the BitcoinFi ecosystem. This includes focus on integrating other ecosystem partners, like the recently announced integration of yield protocol, Acre, and wallet partners to enable a fulsome BitcoinFi experience, like the recently announced ability for Mezo users to “log in” with Bitcoin using both hardware wallets and web wallets like Unisat, OKX, and Xverse. Ledger plans to integrate Mezo directly into its suite of products with further details on integrations to be disclosed in the near future.

Matt Luongo, CEO of Thesis & Founder of Mezo, commented on today’s news: “Ledger Cathay Fund’s support for Mezo is a strong testament that BitcoinFi is the future of ownership, that Mezo is the leader in building the technology behind this future. Today is a tremendous milestone in our work with investors and peers to expand the Bitcoin network, bringing on-chain a circular economy that empowers people worldwide to put BTC to work.”

Mezo, built by Thesis, amplifies Bitcoin‘s infrastructure by facilitating cheap, efficient transactions. In turn, it preserves the Bitcoin network’s foundational principles, including security, dedication to open-source development, and a BTC-first HODL mentality. Distinct from other Bitcoin L2s, Mezo provides users access to applications usable in the real world. Features include Thesis-built tBTC, which allows for trust-minimized bitcoin bridging to numerous ecosystems, plus staking with stBTC, supported by Acre, Thesis’ recently launched Bitcoin-in, Bitcoin-out staking platform.

Mezo serves as a venue for users to maximize Bitcoin‘s full potential beyond being a store of value. Users can leverage applications to transact securely with Bitcoin without roadblocks like fragmented user experience and high gas fees. To date, Mezo has $124.5M in total volume locked and 2,152 Bitcoin deposited in the protocol.

Thesis, one of the longest standing Bitcoin builders, founded in 2013, has supported multiple brand launches of projects within the Bitcoin ecosystem including Mezo, Acre, tBTC, and Fold – who recently announced its plans to go public as the first pureplay financial services company powered by Bitcoin.

Investor Quotes:

Pascal Gauthier, Chairman and CEO of Ledger: “At Ledger, we are Bitcoiners and we believe Bitcoin is the  event. But the landscape of Bitcoin is changing. People want to do more with their Bitcoin, and we need to not only support these new developments in Ledger products, but actively support the future of Bitcoin development. We are therefore thrilled to invest in Mezo, a groundbreaking Bitcoin project that we believe will significantly impact the Bitcoin ecosystem. This investment signals our confidence in Thesis and their project, Mezo, based on their long standing track record of building successful brands in the Bitcoin ecosystem.”

Marguerite de Tavernost, Investment Director at Ledger Cathay Fund: “We really believe in Mezo’s unique vision to supercharge Bitcoin to become an economic layer. Thanks to all the synergies created by their Thesis incubator, Mezo can be the core element of this ecosystem, and create network effects from their decentralized bridge with tBTC to their consumer app with Fold. We were truly impressed by this unique positioning, combined with the very impressive execution capabilities of the Mezo team.”

David Toh, Managing Partner of Mirana Ventures, Mantle EcoFund’s operator: “Investing in Mezo perfectly aligns with Mantle’s vision of supporting and scaling innovations in the Bitcoin ecosystem. We have confidence in Mezo and the synergistic projects led by the Thesis team. We look forward to fostering Mezo’s growth through potential strategic collaborations with projects within the Mantle ecosystem, such as Ignition ($FBTC) and Mantle LSP (Mantle’s Liquid Staking Protocol).”

About Ledger Cathay Fund:

Ledger Cathay Fund is an early-stage venture fund that provides capital to emerging startups in the Web3 ecosystem, while delivering at the same time unique value added to founders. The fund invests at Seed and Series A in companies across the globe  both in equity and tokens.

The fund is the alliance of market leader Ledger for digital assets custody and of global venture capital firm Cathay Innovation. This initiative provides founders with the benefits of the industry support of Ledger together with the long-term investment practice of Cathay Innovation.

About Ledger:

Celebrating its 10 year anniversary in 2024, Ledger is the world leader in Digital Asset security for consumers and enterprises. Ledger offers connected devices and platforms, with more than 6M devices sold to consumers in 180 countries and 10+ languages, 100+ financial institutions and commercial brands. Over 20% of the world’s crypto assets are secured by Ledger.

Ledger is the digital asset solution secure by design. The world’s most internationally respected offensive security team, Ledger Donjon, is relied upon as a crucial resource for securing the world of Digital Assets. With over 14 billion dollars hacked, scammed or mismanaged in 2023 alone, Ledger’s security brings peace of mind and uncompromising self-custody to its community.

Don’t buy “a hardware wallet.” Buy a LEDGER™ device.

LEDGER™, LEDGER LIVE™, LEDGER RECOVER™, LEDGER STAX™, LEDGER FLEX™ and LEDGER FREE FROM COMPROMISE™ are trademarks owned by Ledger SAS

Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Ledger is under license. E Ink® is a registered trademark of E Ink Corporation.

About Mezo: 

The market has been dominated by technology-first approaches that often overlook the economic needs of users. As the world’s first Bitcoin Economic Layer, Mezo introduces a pivotal shift, designed to amplify Bitcoin‘s infrastructure while adhering to its foundational principles to serve its holders. Mezo is Bitcoin native, facilitating cheap and fast transactions for a variety of relevant use cases. This not only enhances the network’s resilience but also ensures it serves the broader economic ambitions of Bitcoin holders. Mezo is the place where we can unlock the full potential of Bitcoin. This is your invitation to create your own economy. Learn more about Mezo’s initiatives and unique features on their blog here.

About Thesis:

Thesis is a venture production studio, funding and building brands on Bitcoin. Thesis has supported multiple successful brands including the launch of Mezo — a new leading Bitcoin L2 — as well as Acre, tBTC, Fold, among others. Thesis has also garnered investments from leading Venture Capital firms including a16z, Polychain Capital, ParaFi, Fenbushi and more. To learn more, please visit: https://thesis.co/

Media contact: [email protected] 

SOURCE Thesis

The Series A financing was led by iGan Partners and included new strategic investors, Eli Lilly and Company and Topcon Healthcare, Inc., along with existing investors, Gentex Corporation, the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator, Verge HealthTech Fund, University of Minnesota’s Discovery Capital, Ontario Brain Institute, Centre for Aging + Brain Health Innovation, and private investors. This financing brings RetiSpec’s total fundraising to $17M USD.

RetiSpec’s clinically validated test aims to help healthcare providers predict amyloid burden, a core biomarker of Alzheimer’s disease. The test is now available for Research Use Only, it is expected to be utilized in routine clinical office visits globally in the near future. RetiSpec’s AI solutions applied to non-invasive retinal images, provide real-time assessments at the point of care. The company’s goal is to also develop additional AI-driven diagnostics for neurodegenerative diseases and side effects of Alzheimer’s therapeutics.

In related developments, RetiSpec will take part in the upcoming Bio-Hermes-002 study sponsored by the Global Alzheimer’s Platform Foundation (GAP). The study aims to investigate the relationship between novel markers of Alzheimer’s disease, including RetiSpec’s test, and the gold standard for diagnosis across a sample of 1,000 cognitively normal and impaired participants. Bio-Hermes-002 is expected to include an unprecedented number of participants from traditionally underrepresented populations in Alzheimer’s studies in order to benefit everyone impacted by Alzheimer’s and related dementias.

Along with the financing, RetiSpec is pleased to welcome Lance Patton, Chief Commercial Officer at Topcon Healthcare, Inc., to its board of directors. His 28 years of expertise in driving adoption of diagnostic imaging technologies via eyecare settings will be invaluable as RetiSpec continues to scale and bring its innovative solutions to market.

“The closing of this Series A financing is a testament of the significant strides we’ve achieved and marks a significant step forward in our mission to enable widespread early and accurate detection of neurodegenerative disease markers with our innovative AI-driven eye test,” said Eliav Shaked, Co-founder and CEO of RetiSpec. “We are thrilled to welcome such strong new investors, alongside existing investors, such as Gentex, who have been key contributors throughout our journey. Together, this investment will allow us to accelerate the commercialization of our AI-driven eye test, which has the potential to transform patient outcomes and enable early, accurate, and equitable access to treatment”.

About RetiSpec

RetiSpec is a Toronto-based medical AI company that aims to enable widespread early and accurate detection of neurodegenerative disease markers through a simple eye exam. RetiSpec’s AI solutions applied to non-invasive retinal images, provide real-time results at the point of care. RetiSpec’s first clinically validated AI is intended to predict amyloid burden to aid in the evaluation of individuals for Alzheimer’s disease. RetiSpec’s AI solutions are currently available for Research Use Only.

RetiSpec acknowledges generous support from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator, Davos Alzheimer’s Collaborative, University of Minnesota’s Center for Drug Design, Ontario Brain Institute, and Centre for Aging + Brain Health Innovation. For more information on RetiSpec, visit retispec.ai.

SOURCE RetiSpec Inc.

BRISBANE, Calif., July 26, 2024 — ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a $30 million Series A financing, bringing the total raised so far to $54M, including the seed financing in 2021. The financing was led by Lapam Capital with strong support from existing investors CDH Investments, 5Y Capital, and Yael Capital, as well as new participants XtalPi and the Charcot-Marie Tooth Research Foundation (CMTRF).

These funds will be used to further augment ReviR’s AI-driven drug discovery VoyageR platform, which will be leveraged to advance proprietary chemical matter for novel and undruggable targets and to support clinical development of treatments for Huntington’s disease (HD), Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders.

Since its founding in 2021, ReviR Therapeutics has assembled an expert global drug discovery team and built a robust customized AI platform. ReviR’s platform strategy focuses on developing non-invasive, orally administered genetic therapies that use small molecules to regulate RNA splicing and influence protein expression. This approach leverages the VoyageR platform to develop potent, safe, and selective RNA splicing modulators for a broad range of diseases.  

While over 80% of disease-related proteins are considered “undruggable”, ReviR’s novel genetic therapies target RNA, upstream of protein synthesis to stop causal disease progression. Other genetic therapy modalities often encounter delivery challenges, particularly with crossing the blood-brain barrier, and can be invasive, especially for CNS diseases. ReviR is currently focused on treating neurodegenerative diseases and rare genetic disorders while exploring partnerships in the fields of oncology, immunology & inflammation, and metabolic diseases. 

Dr. Peng Yue, Co-founder and CEO of ReviR Therapeutics, stated, “Neurological diseases affect a large number of individuals worldwide, many of which do not have disease modifying therapies available. ReviR is dedicated to developing accessible, safer genetic therapies that can be administered orally. We value the support from new and existing investors as we progress from initial platform development to clinical trials, continually enhancing our AI platform and advancing our pipeline. As we move forward, we will continue to raise funds as an extension to our Series A to support additional programs entering clinical trials.”

Mr. Zhihua Yu, Founding Partner of Lapam Capital, commented, “Small molecule targeting RNA represents a highly challenging and innovative field. RNA targets offer greater potential compared to protein targets, but also present higher development difficulties. We have great confidence in ReviR’s platform, which can identify potential RNA targets and efficiently develop safe and effective RNA-targeted therapies. This enables the development of orally administrable small molecule drugs for previously undruggable targets. ReviR has built a team with extensive experience in computational biology, RNA biology, and drug discovery, showcasing exceptional execution capabilities. We are confident the company will advance its pipeline to clinical trials soon, benefiting patients worldwide. We will continue to support ReviR with our experience and resources as it grows.” 

Dr. Shuhao Wen, Co-founder and Chairman of XtalPi, added, “At XtalPi, we recognize the immense potential of small molecule targeting RNA to significantly expand the boundaries of drug discovery. Our collaboration with ReviR, leveraging XtalPi’s cutting-edge AI and robotics drug discovery solutions with ReviR’s specialized capabilities in RNA structural analysis, small molecule screening, and target engagement evaluation, has already yielded promising pipeline results. Our collective expertise is aimed at propelling these innovations into clinical research, tapping into the vast and underexplored potential of RNA targets, and delivering effective novel therapeutic options to patients worldwide.”

About ReviR Therapeutics

ReviR Therapeutics is an emerging biopharmaceutical company focused on the development of RNA-targeting small molecule therapies that modulate the causal genes of diseases, including CNS diseases, cancer, and other rare genetically-defined diseases. The company is utilizing cutting-edge technologies to develop therapies with the goal of developing disease modifying therapies that are highly specific, efficacious, and safe. The company’s initial focus is to apply SpliceR modulation technologies towards RNA targets of genetic diseases with limited or no treatment options. ReviR Therapeutics was founded in 2021 by leaders in computational biology, AI/ML, RNA biology, and drug discovery. The company is headquartered in Brisbane, CA. For more information, visit our website www.revirtx.com or email [email protected].

About Lapam Capital

Lapam Capital is a leading healthcare venture capital firm managing six funds with more than 1.5 billion dollars under management. Lapam Capital focuses on investments in early to mid- stage fast-growing companies that have innovative pharmaceuticals and medical devices. Its investment portfolio currently consists of 120+ projects, of which innovative drug therapeutics projects account for over 80%, including Betta Pharma, RemeGen Co. Ltd., Gyre Therapeutics, Asieris Pharmaceuticals, ImmuneOnco Biopharmaceuticals, Binhui Biotech, Biostar Pharmaceuticals, Eyebright Medical Technology Ltd., and many other companies with great potential. Lapam Capital has a professional investment team with more than 20 years of international and domestic biopharmaceutical industry R&D and management experience and can provide comprehensive value-added support for the invested companies.

About XtalPi Inc.

XtalPi Inc. (“QuantumPharm”, stock code: 2228.HK) is a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform company. Established in 2015 by three postdoctoral physicists at Massachusetts Institute of Technology (MIT), the Company is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. The Company combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally.

About Charcot-Marie Tooth Research Foundation

CMT Research Foundation (CMTRF) is a patient-led, non-profit focused on delivering treatments and cures for CMT. The foundation identifies significant obstacles or deficiencies impeding progress toward a cure and seeks out collaborators to address these issues. To date, CMTRF has funded 24 projects, of which 8 are completed. Of those 8 completed projects, 5 have clinical candidates. CMTRF’s mission to invest in promising science with high potential of leading to treatments and cures was proven effective and ground-breaking when DTx Pharma with a CMTRF- backed program as its lead candidate was acquired by Novartis for $1 billion. Founded by two patients who are driven to expedite drug delivery to people who live with CMT, the 501(c)(3) federal tax-exempt organization is supported by personal and corporate financial gifts. 

SOURCE ReviR Therapeutics

Ian Davis Will Use His Grant to Build an Affordable, User-Assembled Prosthetic Hand Device

GREENWICH, Conn., July 26, 2024 — O’Shaughnessy Ventures LLC (OSV), an investment firm that empowers creators, has awarded an O’Shaughnessy Fellowship to Ian Davis, a product design engineer based in Oregon.

Davis will continue to design, develop and bring to market an affordable prosthetic hand, incorporating his engineering expertise and real-world experience as an amputee, to improve upon currently available devices. He intends to offer the device as an assembly-required DIY kit, enabling users to assemble, fit and repair it independently.

Davis is a self-employed product design engineer with 28 years of experience operating a fabrication and machine shop in Oregon. In 2019, Davis had four fingers on his left hand amputated but was unable to find a prosthetic device that fully met his needs. That experience set him on a mission to build a device of his own, and Davis has been documenting his progress on YouTube ever since.

OSV’s founder and CEO, Jim O’Shaughnessy, commented, “Ian has a rare combination of domain knowledge and personal experience with regard to prosthetics and is perfectly positioned to bring this potentially life-changing device into the world. We’re delighted to be able to support him in bringing this idea to fruition.”

“I’m hugely thankful to OSV,” said Davis. “This is an amazing opportunity, which will allow me, at an accelerated rate, to build something that has the potential to vastly improve the lives of fellow amputees.”

About the Fellowship Program

OSV launched the O’Shaughnessy Fellowships in 2023. It is a one-year program for ambitious people who want to build something great. Fellows receive a $100,000 grant and access to OSV’s network of founders, investors and experts to support them in bringing their projects to life. More information about last year’s Fellows is available on OSV’s website.

In 2024, OSV will award ten $100,000 Fellowships. Applicants for the Fellowships will also be considered for its sister program, the O’Shaughnessy Grants. Under this program, OSV will make twenty additional $10,000 grants to promising creators, who will also be provided with access to OSV’s network.

Applications for the 2024 Fellowships are now closed and will reopen on January 1, 2025. Creators interested in learning more can visit OSV’s website.

About O’Shaughnessy Ventures

OSV is a creative investment firm that empowers and inspires creators to bring their ideas to life. Founded by Jim O’Shaughnessy, a pioneer in quantitative investing, founder of O’Shaughnessy Asset Management, and author of four books on investing, OSV aims to provide financial support and to partner in growing the next life-changing creative ideas.

OSV combines Jim’s deeply rooted interest in all things art, science, investing, and tech with his long-held desire to establish scenarios designed to help promising creators and their inspiring ideas succeed, regardless of age, location, job history, or level of education. For more information, visit https://www.osv.llc.

Media Contact:
Ena Gong
O’Shaughnessy Ventures LLC
(917) 355-7420
[email protected]

SOURCE O’Shaughnessy Ventures

-Applied Intuition cierra más de 300 millones de dólares en una ronda secundaria y da la bienvenida a un nuevo inversor, Fidelity Management & Research Company 

MOUNTAIN VIEW, Calif., 26 de julio d 2024 — Applied Intuition, un proveedor de software para vehículos con sede en Silicon Valley para las industrias automotriz, de transporte por carretera, de construcción, minera, agrícola y otras, anunció hoy que ha cerrado una ronda secundaria de más de 300 millones de dólares y da la bienvenida a Fidelity Management & Research Company como nuevo inversor. También participaron los inversores existentes General Catalyst, BOND, Lux Capital y Elad Gil. Como parte de la venta secundaria, los inversores compraron acciones de empleados actuales, ex empleados y primeros inversores.

“Es fantástico contar con el apoyo de inversores institucionales de primer nivel y a largo plazo”, afirmó Qasar Younis, cofundador y consejero delegado de Applied Intuition. “Esta ronda secundaria es un testimonio de nuestro crecimiento y marca nuestra tercera oferta pública de adquisición con algunos de nuestros mayores accionistas: nuestros empleados. Reclutar talento de primera clase y recompensarlos por su arduo trabajo es un sello distintivo del éxito de Silicon Valley”.

La ronda secundaria, con exceso de oferta, se produce poco después de que Applied Intuition recaudara 250 millones de dólares en la Serie E, anunciada en marzo. La financiación de la Serie E se está utilizando para hacer crecer el equipo de Applied Intuition y expandir la cartera de productos impulsados por IA de la empresa para seguir satisfaciendo las necesidades de los clientes.

“Applied Intuition avanza a toda velocidad y se beneficia de la extraordinaria confluencia de la IA, la conducción autónoma y la electrificación”, afirmó Peter Ludwig, cofundador y director de tecnología de Applied Intuition. “Todos los clientes que conocemos quieren fabricar productos a prueba de futuro y nos consideran un socio de misión crítica”.

2024 ya se perfila como otro año trascendental para Applied Intuition. La empresa lanzó recientemente una solución de pila de autonomía todoterreno que permite una navegación segura en terrenos complejos y no estructurados, una herramienta de IA generativa que crea escenarios de simulación hasta 40 veces más rápido, un software de prueba de hardware en el circuito y una solución de desarrollo de estacionamiento automatizado. La empresa también anunció asociaciones con Porsche AG y Audi, lo que demuestra aún más la confianza de los fabricantes de equipos originales de automóviles en la marca.

Acerca de Applied Intuition 

Applied Intuition es un proveedor de software para vehículos de primer nivel que acelera la adopción de máquinas seguras e inteligentes en todo el mundo. Fundada en 2017, Applied Intuition ofrece la cadena de herramientas ADAS/AD definitiva, una plataforma para vehículos de primera clase y un conjunto de herramientas de autonomía para ayudar a los clientes a acortar el tiempo de comercialización, construir sistemas de alta calidad y crear experiencias de consumo de próxima generación. Dieciocho de los 20 principales fabricantes de automóviles del mundo confían en las soluciones de Applied Intuition para impulsar la producción de vehículos modernos. Applied Intuition presta servicios a las industrias de automoción, transporte por carretera, construcción, minera, agrícola y de defensa y tiene su sede en Mountain View, California, con oficinas en Ann Arbor y Detroit, Michigan, Washington, D.C., Múnich, Estocolmo, Seúl y Tokio. Más información en appliedintuition.com.

Foto – https://mma.prnewswire.com/media/2468675/Applied_Intuition_funding.jpg

RALEIGH, N.C., July 25, 2024 — Medicom, a health tech startup leading enterprise imaging interoperability, today announced completion of its oversubscribed strategic financing round. Notable participation included UPMC Enterprises, Tampa General Hospital (TGH) Ventures, expanded participation from existing investors Cone Health Ventures, Oval Park Capital and Grayhawk Capital, as well as local Triangle venture groups such as the Carolina Angel Network and the Triangle Tweener Fund.

With participation from two nationally renowned academic institutions—UPMC Enterprises, the innovation, commercialization, and venture capital arm of the health system UPMC (University of Pittsburgh Medical Center), and TGH Ventures, the corporate venture capital arm of Tampa General Hospital—Medicom welcomes the strategic partnerships and the clinical and research expertise they bring as the company enters its next phase of growth.

“As we continue to strengthen our core enterprise imaging interoperability platform and unlock transformative insights from Real-World Data, we are excited to have two extraordinary partners join our team,” said Michael Rosenberg, Co-Founder and CEO of Medicom. “Medicom’s alignment with UPMC’s and TGH’s missions around interoperability and RWD&E will accelerate the platform’s evolution and commercialization, and we are excited to see the impact these partnerships will have on our thousands of Medicom Connect and Intellect user organizations.”

“At UPMC Enterprises, we have a front row seat to the transformation that health care is undergoing as data becomes more accessible and interoperability improves,” said Brent Burns, Executive Vice President of digital solutions at UPMC Enterprises. “Medical imaging files and metadata are critical to supporting clinical and academic research to develop novel therapeutics. We are thrilled to partner with Medicom and bring their expertise in secure and efficient medical image and data exchange to support UPMC’s continued leadership in health care research.” 

“Since 2021, Tampa General Hospital has expanded its deployment with Medicom to offer a comprehensive singular, high reliability enterprise imaging platform that facilitates cross-institute exchange across all 23 TGH Imaging locations in the Tampa Bay region,” said Sherri Lewman, senior vice president of Enterprise Imaging. “Broadening our scope with Medicom has allowed TGH Imaging to increase telemetry, observability and control while reducing overall image exchange costs.”

“TGH Ventures is proud to approve this investment in Medicom to continue to advance innovation across our enterprise and all aspects of healthcare imaging,” said Rachel Feinman, vice president of Innovation at Tampa General and managing director of TGH Ventures.

In addition, Medicom secured capital from Customers Bank, the $22 billion asset subsidiary of Customers Bancorp and a leading partner in the venture banking community. 

This round of funding aims to leverage strategic partnerships with leading academic institutions and local Research Triangle Park participants, alongside the deployment of new capital, to drive platform innovation and go-to-market functions for accelerated growth.

Recognized by KLAS as one of the most promising HCIT companies in 2024, Medicom’s platform addresses the long-standing challenges of interoperability of medical images and relevant clinical data. By leveraging its unique peer-to-peer network and generative AI, Medicom consolidates the use of multiple cloud solutions, CDs, fax, courier services, and VPNs into a single enterprise-wide platform for all enterprise imaging workflows. Whether it’s automatically capturing relevant prior images and associated clinical data before a patient’s appointment and reconciling it across all internal systems, enabling patients with the ability to access and share their images directly within their existing patient portal, or providing researchers with longitudinal patient-cohort specific de-identified data for research and development, Medicom ensures real-time access to relevant data for the advancement of patient care.

About Medicom
Medicom is a health tech company that is dedicated to ensuring timely access to clinically relevant data at the point-of-care and advancing research. The company developed the first fully federated, decentralized, peer-to-peer network for medical image and clinical data exchange. The Medicom platform leverages the Medicom Network for both clinical and research use cases. Medicom Connect enables enterprise imaging interoperability, eliminating long-standing data exchange, accessibility, and usability challenges for patients and providers. Medicom Intellect leverages the Medicom Network for research collaboration, providing data and insights for research within precision medicine and life sciences.

Related Links
https://home.medicom.us
https://enterprises.upmc.com
https://tgh.org/research-and-innovation/tgh-ventures

Provided by:
Medicom Technologies, Inc. (Medicom) // Raleigh, NC & Phoenix, AZ

SOURCE Medicom Technologies, Inc.

The newest release of the world’s only commercial simulation software for extremely large-scale and rapid design and analysis of ion traps

• Purpose-built simulation software for design and development of ion traps
• Additional features, including planar and rotational symmetries and double ground plane symmetries, accelerate simulations and reduce memory requirements by 16X
• Extended support for Red Hat Enterprise Linux 9 and Ubuntu

IRVINE, Calif., July 25, 2024 — Nullspace, Inc., a Computer-Aided Engineering (CAE) software company, announced today the new release of Nullspace ES, the world’s only commercial simulation software for extremely large scale, rapid, and accurate design and analysis of ion traps for quantum computing applications.

Historically, the lack of robust design tools and complex experiments, forced engineers to develop relatively simple ion trap architectures. Legacy simulation tools are not purpose-built for ion trap design, and lead to higher prototyping costs and longer production schedules and limiting the accuracy and scalability of ion trap designs, thus limiting advancements in quantum computing.

Nullspace ES was developed by top electromagnetics and ion-trap design experts. Today it is used by leading companies and universities spearheading innovation in ion trap-based technology for quantum computers.

“Nullspace ES has been a game-changer for our design work,” says Dr. Björn Lekitsch, a researcher at the AG Quantum Group in Johannes Gutenberg Mainz University. “It allows us to simulate how our ion traps behave in order to calculate and predict the ion movement more precisely. With Nullspace ES software, we can explore the effects of varying geometries and configurations on the ion behavior, which is critical for enhancing the performance and scalability of our quantum computing systems.“

The latest release of Nullspace ES, along with its CAD design and meshing companion tool, Nullspace Prep, includes a new, faster, and more efficient meshing algorithm. Meshing is a key step to ensure users obtain high accuracy results. Nullspace’s meshing technology is tailored for the ion trap community and efficiency in both meshing time and meshing quality gives users confidence in high accuracy results leading to reduced prototyping demands.

Nullspace ES 2024 R1 provides powerful geometric symmetry features including planar and rotational symmetries. The new release adds double ground plane symmetries, and these features can be used in combination. Leveraging Nullspace’s new symmetry workflows can speed up simulations and reduce memory requirements by factors of up to 16X for ion trap simulations.

The newest Nullspace ES release adds support for Red Hat Enterprise Linux 9, expanding support for all current Red Hat and Ubuntu-based Linux operating systems.

For more information on Nullspace ES visit: https://www.nullspaceinc.com/nullspace-es. To schedule a demo of Nullspace software: www.nullspaceinc.com/contact.

Press Contact
Masha V. Petrova
[email protected]

SOURCE Nullspace, Inc

MOUNTAIN VIEW, Calif., July 25, 2024 — Applied Intuition, a Silicon Valley-based vehicle software supplier for automotive, trucking, construction, mining, agriculture and other industries, today announced it has closed a secondary round of over $300 million and welcomes Fidelity Management & Research Company as a new investor. Existing investors General Catalyst, BOND, Lux Capital and Elad Gil also participated. As part of the secondary sale, investors purchased equity from current employees, former employees, and early investors.

“It’s fantastic to have the support of top-tier, long-term institutional investors,” said Qasar Younis, co-founder and CEO of Applied Intuition. “This secondary round is a testament to our growth, and it marks our third tender offer with some of our biggest shareholders — our employees. Recruiting world-class talent and rewarding them for their hard work is a hallmark of Silicon Valley’s success.”

The oversubscribed secondary round comes on the heels of Applied Intuition raising a $250 million Series E announced back in March. The Series E funding is being used to grow Applied Intuition’s team and expand the company’s AI-powered product portfolio to continue meeting customer needs.

“Applied Intuition is going full speed ahead and benefiting from the extraordinary confluence of AI, autonomous driving, and electrification,” said Peter Ludwig, co-founder and CTO of Applied Intuition. “Every customer we meet wants to build future-proof products and looks to us as a mission-critical partner.”

2024 is already shaping up to be another momentous year for Applied Intuition. The company recently launched an off-road autonomy stack solution enabling safe navigation of complex unstructured terrain, a generative AI tool that creates simulation scenarios up to 40 times faster, a hardware-in-the-loop testing software and an automated parking development solution. The company also announced partnerships with Porsche AG and Audi, further demonstrating automotive OEM trust in the brand.

About Applied Intuition

Applied Intuition is a Tier 1 vehicle software supplier that accelerates the adoption of safe and intelligent machines worldwide. Founded in 2017, Applied Intuition delivers the definitive ADAS/AD toolchain, a world-class vehicle platform and an autonomy stack to help customers shorten time to market, build high-quality systems and create next-generation consumer experiences. Eighteen of the top 20 global automakers trust Applied Intuition’s solutions to drive the production of modern vehicles. Applied Intuition serves the automotive, trucking, construction, mining, agriculture and defense industries and is headquartered in Mountain View, Calif., with offices in Ann Arbor and Detroit, Mich., Washington, D.C., Munich, Stockholm, Seoul and Tokyo. Learn more at appliedintuition.com.

SOURCE Applied Intuition